Unfortunately, I have to agree. Someone posted as the cap raise...

Unfortunately, I have to agree. Someone posted as the cap raise was beginning to unravel that some sophs at the big end of town had been seriously put out by the way Cellmid had gone about their business, and there would be no grace granted in future. I suspect they may be reaping a little of that sowing now.

Their failure to extract value from Lyramid and the midkine portfolio to date is bordering on negligent - something that should have held so much benefit, both in medical terms and in the $ that would follow (and was the reason I invested in the first place), was relegated to second place in favour of chasing the shiny, happy cosmetics market. Fair play, but now, just as that cosmetics cash cow is beginning to generate some positive cashflow, the reason for its existence is to be pawned off, at a fraction, no doubt, of its intrinsic value.

Still, at least the CEO has been kept in the manner to which she's accustomed through it all........